Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

bgp products - terazosin hydrochloride dihydrate 1.187mg equivalent to 1 mgterazosin;  ; terazosin hydrochloride dihydrate 2.347mg equivalent to 2 mg terazosin; terazosin hydrochloride dihydrate 5.935mg equivalent to 5 mg terazosin - tablet - active: terazosin hydrochloride dihydrate 1.187mg equivalent to 1 mgterazosin   excipient: lactose monohydrate magnesium stearate maize starch purified talc starch active: terazosin hydrochloride dihydrate 2.347mg equivalent to 2 mg terazosin excipient: lactose monohydrate magnesium stearate   maize starch quinoline yellow starch active: terazosin hydrochloride dihydrate 5.935mg equivalent to 5 mg terazosin excipient: iron oxide red lactose monohydrate magnesium stearate maize starch purified talc starch

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

abbott laboratories (nz) ltd - terazosin hydrochloride dihydrate 11.87mg equivalent to 10 mg terazosin - tablet - 10 mg - active: terazosin hydrochloride dihydrate 11.87mg equivalent to 10 mg terazosin excipient: indigo carmine lactose monohydrate magnesium stearate maize starch purified talc

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

abbott laboratories (nz) ltd - terazosin hydrochloride dihydrate 1.187mg equivalent to 1 mg terazosin - tablet - 1 mg - active: terazosin hydrochloride dihydrate 1.187mg equivalent to 1 mg terazosin excipient: lactose monohydrate magnesium stearate maize starch purified talc

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

viatris limited - terazosin hydrochloride dihydrate 2.347mg equivalent to 2 mg terazosin - tablet - 2 mg - active: terazosin hydrochloride dihydrate 2.347mg equivalent to 2 mg terazosin excipient: lactose monohydrate magnesium stearate maize starch purified talc quinoline yellow starch - the symptomatic and pathophysiologic treatment of benign prostatic hyperplasia (bph) when: -prostatectomy is not indicated -patient is not fit for surgery -elective surgery must be postponed (e.g., waiting list) -patient refuses surgical treatment.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

viatris limited - terazosin hydrochloride dihydrate 5.935mg equivalent to 5 mg terazosin - tablet - 5 mg - active: terazosin hydrochloride dihydrate 5.935mg equivalent to 5 mg terazosin excipient: iron oxide red lactose monohydrate magnesium stearate maize starch purified talc starch - the symptomatic and pathophysiologic treatment of benign prostatic hyperplasia (bph) when: -prostatectomy is not indicated -patient is not fit for surgery -elective surgery must be postponed (e.g., waiting list) -patient refuses surgical treatment.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - alfuzosin hydrochloride, quantity: 10 mg - tablet, modified release - excipient ingredients: magnesium stearate; ethylcellulose; microcrystalline cellulose; iron oxide yellow; silicon dioxide; mannitol; hypromellose; hydrogenated castor oil; povidone - indicated for the treatment of the functional symptoms of benign prostatic hyperplasia.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - prazosin hydrochloride, quantity: 5.476 mg (equivalent: prazosin, qty 5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; magnesium stearate; sodium lauryl sulfate; maize starch - indications as at 31 april 2004: in patients with hypertension. minipress (prazosin hydrochloride) is indicated in the treatment of hypertension of varied aetiology and all grades of severity. it can be used as the initial and sole agent or it may be employed in a treatment programme in conjunction with other antihypertensive agents. renal blood flow and glomerular filtration rate are not impaired by long-term oral administration. minipress can be used with safety in hypertensive patients with impaired renal function. in patients with congestive heart failure. minipress is indicated in the treatment of severe refractory congestive heart failure. minipress may be added to the therapeutic regime in those patients who have become refractory to conventional therapy with cardiac glycosides and diuretics. in patients with raynaud's phenomenon and raynaud's disease. minipress is indicated in the treatment of raynaud's phenomenon and raynaud's disease. benign prostatic hyperplasia. minipress is indicated as an adjunc

Australie - anglais - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - prazosin hydrochloride, quantity: 2.19 mg (equivalent: prazosin, qty 2 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; magnesium stearate; sodium lauryl sulfate; maize starch - indications as at 30 april 2004: in patients with hypertension. minipress (prazosin hydrochloride) is indicated in the treatment of hypertension of varied aetiology and all grades of severity. it can be used as the initial and sole agent or it may be employed in a treatment programme in conjunction with other antihypertensive agents. renal blood flow and glomerular filtration rate are not impaired by long-term oral administration. minipress can be used with safety in hypertensive patients with impaired renal function. in patients with congestive heart failure. minipress is indicated in the treatment of severe refractory congestive heart failure. minipress may be added to the therapeutic regime in those patients who have become refractory to conventional therapy with cardiac glycosides and diuretics. in patients with raynaud's phenomenon and raynaud's disease. minipress is indicated in the treatment of raynaud's phenomenon and raynaud's disease. benign prostatic hyperplasia. minipress is indicated as an adjunc

Australie - anglais - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - prazosin hydrochloride, quantity: 1.095 mg (equivalent: prazosin, qty 1 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; magnesium stearate; sodium lauryl sulfate; sunset yellow fcf; maize starch - indications as at 30 april 2004: in patients with hypertension. minipress (prazosin hydrochloride) is indicated in the treatment of hypertension of varied aetiology and all grades of severity. it can be used as the initial and sole agent or it may be employed in a treatment programme in conjunction with other antihypertensive agents. renal blood flow and glomerular filtration rate are not impaired by long-term oral administration. minipress can be used with safety in hypertensive patients with impaired renal function. in patients with congestive heart failure. minipress is indicated in the treatment of severe refractory congestive heart failure. minipress may be added to the therapeutic regime in those patients who have become refractory to conventional therapy with cardiac glycosides and diuretics. in patients with raynaud's phenomenon and raynaud's disease. minipress is indicated in the treatment of raynaud's phenomenon and raynaud's disease. benign prostatic hyperplasia. minipress is indicated as an adjunc

Australie - anglais - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - tamsulosin hydrochloride, quantity: 400 microgram - tablet, modified release - excipient ingredients: colloidal anhydrous silica; macrogol 8000; macrogol 7000000; hypromellose; butylated hydroxytoluene; iron oxide yellow; magnesium stearate - for the relief of lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph).